Creative Medical Technology shares are trading lower after the company announced top line pilot study results for the StemSpine procedure using AlloStem to treat chronic lower back pain.
Portfolio Pulse from Benzinga Newsdesk
Creative Medical Technology announced top line pilot study results for the StemSpine procedure using AlloStem to treat chronic lower back pain, causing its shares to trade lower.
May 18, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Creative Medical Technology shares are trading lower after announcing top line pilot study results for the StemSpine procedure using AlloStem.
The announcement of the top line pilot study results for the StemSpine procedure using AlloStem has led to a decrease in the stock price of Creative Medical Technology. This is because investors may perceive the results as not meeting expectations or not being as positive as anticipated, leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100